Jinsy Andrews
Director, Amyotrophic Lateral Sclerosis (ALS) Center · NYU Grossman School of Medicine
Credentials: · · · · · ·
History
PresentAmyotrophic Lateral Sclerosis (ALS) Center · NYU Grossman School of Medicine
- Present
Clinical Trials · NYU Grossman School of Medicine
2006–2007Columbia University Mailman School of Public Health
1997–2001- 1993–1997
Research
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
New England Journal of Medicine · 2022 · 755 citations
Neurotherapeutics · 2022 · 153 citations
Study of 962 patients indicates progressive muscular atrophy is a form of ALS
Neurology · 2009 · 149 citations
28 papers
23 papers
18 papers
15 papers
- AW
14 papers
14 papers · 1 as a fellow
14 papers
13 papers
Grants
- 2023–2028
Access for All in ALS (ALL ALS) East Clinical Coordinating Center
National Institute of Neurological Disorders and Stroke · OT2
PI · $71.5M · Massachusetts General Hospital
- 2023–2027
Intermediate-Sized Expanded Access Protocol for CNM-Au8 in Amyotrophic Lateral Sclerosis (ALS).
National Institute of Neurological Disorders and Stroke · U01
Contact PI · $45.1M · New York University School of Medicine
Clinical trials
- 2009
Principal investigator · Terminated · Phase 2, Phase 3
Massachusetts General Hospital
- 2012–2014
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
Study director · Completed · Phase 2
Cytokinetics